CD274 and non-small cell lung carcinoma: In the CITYSCAPE Phase II study for NSCLC, the combination of tiragolumab with a PD-L1 inhibitor improved objective response rates (37% vs. 21%) and progression-free survival compared to PD-L1 blockade alone, highlighting its potential to synergize with existing immunotherapies through complementary mechanisms of T cell activation [137].